



ScienceDirect

Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jval

Systematic Literature Review

Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations from a Societal Perspective

Kimberley Hubens, MSc, Marieke Krol, PhD, Joanna Coast, PhD, Michael F. Drummond, MCom, DPhil, Werner B.F. Brouwer, PhD, Carin A. Uyl-de Groot, PhD, Leona Hakkaart-van Roijen, PhD

ABSTRACT

Objectives: This study aimed (1) to perform a systematic literature review of instruments for measuring productivity loss of paid and unpaid work and (2) to assess the suitability (in terms of identification, measurement, and valuation) of these instruments for use in health economic evaluations from a societal perspective.

Methods: Articles published from 2018 were sourced from PubMed/Medline, PsycInfo, Embase, and Econlit. Using 2 separate search strategies, eligible economic evaluations and validation studies were selected and unique measurement instruments identified. A data-extraction form was developed by studying previous literature and consulting an international panel of experts in the field of productivity costs. This data-extraction form was applied to assess the suitability of instruments for use in economic evaluations.

Results: A total of 5982 articles were retrieved from the databases, of which 99 economic evaluations and 9 validation studies were included in the review. A total of 42 unique measurement instruments were identified. Nine instruments provided quantified measures of absenteeism, presenteeism, and unpaid work. Five instruments supplied the necessary information to enable the use of at least 1 common valuation method. The Health and Labour Questionnaire-Short Form, Health and Labour Questionnaire, and Institute for Medical Technology Assessment Productivity Cost Questionnaire met both criteria. Nevertheless, the developers replaced the Health and Labour Questionnaire-Short Form and Health and Labour Questionnaire by the more recently developed Institute for Medical Technology Assessment Productivity Cost Questionnaire.

Conclusions: Although many instruments for measuring productivity loss were identified, most were not suitable for capturing productivity changes for economic evaluations from a societal perspective. Future research can benefit from this study by making an informed instrument choice for the measurement of productivity loss of paid and unpaid work.

Keywords: economic evaluation, indirect costs, measurement, measurement instruments, productivity costs, productivity loss, questionnaire, survey, systematic review

VALUE HEALTH. 2021; ■(■):■-■

Introduction

Health economic evaluations aim to inform decision-makers about efficient resource allocation.¹ For these evaluations, a societal perspective has frequently been advocated.²⁻⁵ In a societal perspective, all relevant costs and benefits should be included, regardless of who incurs these benefits or costs.⁶ Costs can be categorized as healthcare costs, patient and family costs, costs in other sectors, and productivity costs.⁷ The latter cost category includes costs related to paid and unpaid production loss due to illness, disability, or death of productive persons.⁸

Productivity costs may contribute to a large proportion of total direct and indirect costs of medical conditions.⁹⁻¹¹ Examples include: a cost-effectiveness study of expensive hospital drugs,

which found that productivity costs comprised up to 83% of total costs⁹; a study of cancers in 27 countries in the European Union, which concluded that productivity loss due to early death and lost working days accounted for 41% of total economic burden in 2009 (ie, €52.03 billion)¹⁰; and a study of the costs of hand and wrist injuries of working age people in The Netherlands, which found that productivity costs represented approximately 75% of total costs.¹¹ In some instances, conclusions about the cost-effectiveness of interventions changed depending on the inclusion or exclusion of productivity costs.⁹ Therefore, in an economic evaluation from a societal perspective, excluding these costs could lead to biased cost-effectiveness outcomes.¹² We do note that international consensus on appropriate perspectives to take in economic evaluations and their operationalization is lacking.

Given that obtaining information on productivity loss directly from work sites is usually not feasible,⁴ self-report questionnaires are often used to measure this loss.^{4,13–21} Although researchers can choose from a wide variety of instruments measuring productivity loss, a gold standard is lacking.¹⁴ Country-specific methods guidelines provide different recommendations on the inclusion of productivity costs. For instance, when including productivity costs in economic evaluations, some guidelines state that only absence from work is of interest^{22–24} whereas others also encourage including reduced productivity while at work²⁵ or unpaid work loss.²⁶ Additionally, the methods used to measure productivity loss need to comply with the anticipated valuation method. Recommended valuation methods vary across countries,^{22–25,27,28} resulting in different requirements for measurement instruments.^{8,16,29} It is essential that applied measurement instruments support the ultimate inclusion of the estimated costs in economic evaluations. For instance, many instruments focus primarily on absence from paid work,¹² while authors have encouraged including other components of productivity loss as well.^{30–33} Moreover, some instruments do not provide the necessary information for monetary valuation of productivity loss.¹⁴ Thus, not all measurement instruments may be suitable for including these costs in economic evaluations from a societal perspective.

Some systematic reviews have already been conducted on measurement instruments of productivity costs. For instance, Tang¹⁶ identified 11 generic questionnaires. Mattke et al²¹ found 20 survey instruments that assess the effect of health problems on productivity loss and related costs. Additionally, Ospina et al¹³ identified 21 instruments for measuring reduced productivity while at work. Although these reviews provided insight into different instruments and their characteristics, these did not evaluate the suitability of these instruments for health economic evaluations. Additionally, the current review includes broader search terms, such as unpaid productivity loss. This review aims to add to current knowledge and recommendations by performing a more comprehensive review of the literature and a thorough evaluation of the identified instruments.

Thus, this study aimed to perform a systematic literature review of measurement instruments of productivity loss of paid and unpaid work and to assess their suitability in terms of identification, measurement, and valuation for use in health economic evaluations conducted from a societal perspective.

Methods

A systematic review was performed to identify measurement instruments of productivity loss of paid and unpaid work. This systematic review consisted of 2 search strategies. Measurement instruments were identified from economic evaluations and validation studies. The search of validation studies was added as a separate search since recently developed instruments might not have been applied in economic evaluations yet. This review adopted the transparent Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.³⁴

Search Strategy

Two search strategies were designed to identify relevant studies in PubMed/Medline, PsycInfo, Embase, and Econlit. Both were designed and optimized by an experienced biomedical information specialist (Wichor M. Bramer) at the Erasmus Medical Center, Rotterdam, The Netherlands.

The first search strategy was developed to identify economic evaluations that applied instruments to measure productivity loss.

This strategy contained the following key elements: “productivity loss” and “economic evaluation.” For the purpose of this study, economic evaluations and cost-of-illness studies were included.

The second search strategy was developed to identify validation studies of measurement instruments of productivity loss. This search strategy contained the following key elements: “productivity loss” and “validation study.” For the purpose of this study, validation studies included studies that aimed to assess the measurement properties of 1 or more instrument. The elements of both strategies were extended with controlled vocabulary keywords (eg, MeSH terms in PubMed) and synonyms.

Both searches were restricted to publications from January 2018. This time frame was selected to focus on identifying instruments that were actually used in recent economic evaluations (first strategy). The second search strategy also allowed inclusion of new instruments with an insufficient research longevity to already be observed in the first search strategy. The full search strategies are presented in [Appendices 1 and 2](#) in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.05.002>.

Study Selection

After applying the search strategies to the selected databases on February 14, 2019, duplicate studies were removed using Endnote³⁵ deduplication function. Subsequently, the eligibility of the remaining studies was assessed separately for the 2 searches by 2 researchers independently (K.H. and D.G.) according to the criteria presented in [Table 1](#). First, a pilot screening was performed of 100 references. Then, all titles and abstracts were screened. After that, full texts of the included articles were screened. Discrepancies between the researchers were discussed until consensus was reached. In exceptional cases where consensus could not be reached, a third researcher was consulted (H.P.).

Data Extraction

After the selection of eligible studies, relevant data were extracted using a predesigned data-extraction form. This form was developed by studying previous literature and consulting an international expert panel in the field of productivity costs. Data from the first 20 studies were extracted by 2 researchers (K.H. and D.G.) collaboratively to ensure harmonization. After this pilot, the 2 researchers divided the references and extracted data independently. Any doubts were discussed between the researchers or with a third researcher (H.P.). If information could not be retrieved from the included studies, additional studies and websites were manually searched. If information on an instrument could still not be retrieved, the instrument was excluded from analysis.

The following data were extracted from the included studies from both searches using an Excel-based template: study characteristics (ie, country, study design, time horizon, disease area, diagnosis, age range, mean age, percentage of female respondents, percentage of respondents with paid work, productivity loss of patient/parent/caretaker/other) and measurement instrument (ie, instrument name, version, full or partial instrument used). Unique instruments were selected for analysis if they could be distinguished by their name or items and contained unique questions on productivity loss. If instruments were modified for use in specific studies by others instead of the original authors, only the original instrument was selected, because a preliminary search showed that many articles did not report the specific changes made to the original instruments.

In addition to general instrument characteristics (ie, instrument name and abbreviation, focus of application, mode of administration, number of items in total, number of items on productivity loss, recall period, languages available, online

Table 1. Eligibility criteria for identified studies from the literature search of economic evaluations and validation studies.

| Category* | Criteria for economic evaluations | Criteria for validation studies |
|----------------------|---|--|
| Population | Study subjects were humans | |
| Age | At least some study participants were between 18 and 70 years | |
| Language | Published in English | |
| Availability | Full text was available online | |
| Research methodology | Cost-effectiveness, cost-benefit, cost-utility, or cost-of-illness study | Validation study |
| Productivity loss | One or more components of productivity loss were measured using a specified self-report, proxy-report, or an interviewer-led instrument (ie, instrument name or items was reported) | Study aim was validating a measurement instrument of 1 or more components of productivity loss |
| Exclusion | Abstracts for presentations in meetings and conferences, literature reviews, editorials, corrections, book chapters, unpublished studies, and studies that predicted productivity loss using an instrument with a different outcome measure were excluded | |

*The first 4 and last category contain criteria for both economic evaluations and validation studies.

availability, and conditions of use), other aspects were included to evaluate the suitability for use in health economic evaluations.

Because estimating productivity costs entails (1) identifying relevant costs components, (2) operationalizing the measurement, and (3) expressing production loss in monetary values using common valuation methods,⁷ these steps formed the basis for this part of the data-extraction form.

Identification of relevant cost components

Relevant cost components of productivity loss of paid and unpaid work were identified from previous literature^{8,13,14,16–21,36} and discussed with the expert panel during multiple meetings. The following components were recognized in the literature: absenteeism, presenteeism, unpaid work, compensation mechanisms, and multiplier effects. Although the relevance of the first 3 components was confirmed, the expert panel concluded that there was insufficient clarity about how compensation mechanisms and multiplier effects influence overall productivity costs and to what extent employees are capable of estimating compensation or multipliers during their work absence. Therefore, it was concluded that this review should focus on absenteeism, presenteeism, and unpaid production loss (hereafter referred to as unpaid work). This review assessed whether instruments included these 3 components.

Absenteeism was defined as time absent from work.^{8,16,17,21,36} Although the specific description may vary between studies, instruments should provide information on absence from work, sick days, sick leave, missed work, lost work time, or similar situations.^{16,19,20} This could also be measured by determining the difference between expected and actual work hours.^{14,16} If a distinction was made between missed work because of illness and other reasons, only the first part was of interest for this study.^{18,20}

Presenteeism was defined as reduced productivity while being ill at work.^{8,36} Examples of questions that focus on presenteeism can refer to measuring quality or quantity of production or tasks performed.⁸

Unpaid work was defined as unpaid productive activities that can be replaced by a hired third person.³⁷ This rule of thumb has the purpose of differentiating between what is unpaid work and what is not. Using this definition, examples of unpaid work could

be household tasks, taking care of children, and volunteer work. Nevertheless, leisure time, playing with grandchildren, and studying was not considered unpaid work, because this does not yield production and/or cannot be replaced by a third person.

Operationalizing measurement

To enable valuation, instruments must provide quantified data for the respective components of productivity loss (eg, hours, days, percentages). This review evaluated whether instruments supplied quantified data for absenteeism, presenteeism, and/or unpaid work.

Monetary valuation

To express production loss owing to absenteeism in monetary values, measurement instruments should be suitable for using common valuation methods, namely the human capital method (HCM) and/or the friction cost method (FCM).^{29,38,39}

To enable valuation using the HCM, next to data on direct information on absenteeism, data on long-term disability or premature death of patients, and national retirement age is necessary.^{8,29} Given the availability of data on national retirement age and death of patients, measurement instruments only need to provide information on long-term disability to be suitable for monetary valuation using the HCM. Long-term disability refers to the often permanent, complete or partial inability to perform paid work. This commonly involves the (partial) loss of employment and, in that sense, is distinct from absenteeism where the inability to work is typically temporary and does not involve a loss of employment. Within the FCM, absence from work is only included in cost calculations for the period of time assumed required to replace the ill employee by a substitute; the so-called friction period. Therefore, this period needs to be specified, which can be estimated by using national or international data on vacancy durations. To be suitable for the FCM, a measurement instrument is required to assess absenteeism in more detail and also provide information on the number of periods and duration of absence from work (because new friction periods can start with new periods of absence).¹⁶ This review assessed whether instruments provided the necessary information to apply these valuation methods.

Analysis

An overview of the identified instruments will be presented and their general characteristics and information on the suitability for use in economic evaluations from a societal perspective.

Results

The search of economic evaluations discovered 3496 articles of which 99 were included after title-and-abstract and full-text screening. The search on validation studies identified 2486 articles of which 9 were selected. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagrams for the literature searches are presented in [Figure 1](#). A full list of the included studies and their characteristics may be found in [Appendix 3](#) in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.05.002>.

Study Characteristics

In total, 108 studies were included in this review, including 99 economic evaluations and 9 validation studies. [Table 2](#) presents the summarized study characteristics. Most studies were performed in The Netherlands (28; 26%), the United States (23; 21%), and the United Kingdom (10; 9%). The most common study types were cost-effectiveness studies (49; 45%), cost-of-illness studies (47; 44%), and cost-utility studies (42; 39%) of which some applied more than 1 method. Almost all studies (98; 91%) measured productivity loss of patients, while others focused on caregivers and/or parents.

Included Measurement Instruments

Forty-nine measurement instruments of productivity loss were identified. The economic evaluations applied 34 instruments, and the validation studies reported on 22. Of these, 7 instruments were obtained through both searches.

[Table 3](#) presents the identified instruments, ordered by frequency of use within the selected studies. The Work Productivity and Activity Impairment Questionnaire (WPAI)-General health (WPAI-GH, version 2.0), the WPAI-Specific Health Problem (version 2.0), and the Institute for Medical Technology Assessment (iMTA) questionnaire for Costs associated with Psychiatric Illness were applied most frequently in the included studies. More than half of the instruments (66.7%) were only applied once. From the 13 instruments that were only identified through the included validation studies, the question by Vänni et al,⁴⁰ the Resource Use Questionnaire-Preschool (RUQ-P), and the Work Hoarse were developed recently. Seven instruments were excluded from further analysis. The iMTA questionnaire for Costs associated with Psychiatric Illness was omitted because the iMTA Productivity Cost Questionnaire (iPCQ) was part of this instrument.⁴¹ The Use of Services and Productivity Questionnaire was excluded because this instrument comprised a combination of the original quantity and quality method and the Health and Labour Questionnaire (HLQ).⁴² The Client Service Receipt Inventory and the Client Sociodemographic and Service Receipt Inventory were removed from analysis because the component for measuring productivity loss is an exact copy of the WPAI-GH.⁴³ The Family Health Economic questionnaire⁴⁴ and the WPAI (no version specified) could not be included owing to a lack of information on the items used. Furthermore, the WPAI: GH-Care Giving version 2.0 could not be traced back to the original authors of the WPAI-GH.⁴⁵ Therefore, only the original WPAI-GH was selected. Thus, 42 unique instruments were included in the analysis.

General Instrument Characteristics

The general characteristics of the included instruments are presented in [Table 4](#), sorted by the number of included components of productivity loss.

The number of both generic and disease-specific instruments was 21. Mode of administration was self-administered by patients for all but 7 instruments. The Cost Interview, the MS Questionnaire, and the Work and Health Interview involve interviews of patients. The Family Cost Survey, the Survey by Mumford et al,⁴⁸ and the RUQ-P consist of self-administration by the parent, and the Resource Utilization in Dementia (RUD) self-administration by the caregiver.

The number of items of the instruments ranged from 1 to 436, with an average of 39.8 and a median of 10 items. Notably, some of these instruments did not solely measure productivity loss and included other items as well, for instance the MS Questionnaire (436 items) and the RUQ-P (90 items). The number of items on productivity loss ranged from 1 to 50 items, with an average of 9.3 and a median of 6 items. Furthermore, recall periods of the instruments ranged from 1 day^{87,47} to 2 years.⁴⁰ Most employed a recall period of less than 3 months. Additionally, 1 instrument covered the period from symptom onset until today,⁶⁹ and 1 used a variable period from admission date.⁴⁸ Notably, the instruments which were applied most frequently in the included studies had 6 items on productivity loss and a recall period of 7 days.

All but 3 instruments were available in English. The Cost Interview was only available in German,⁷² the MS Questionnaire was only available in Spanish (Panama),⁶⁹ and the Productivity and Disease Questionnaire (PRODISQ) was only available in Dutch.⁶⁸ Seven instruments were available in more than 7 languages: the iPCQ,⁵⁵ the RUD,⁸⁰ the Valuation of Lost Productivity Questionnaire,⁶⁰ the Work Limitations Questionnaire,⁷⁰ and the 3 versions of the WPAI.⁶²

From the 42 included instruments, 31 (73.8%) were available online. Eight (19.5%) were available online in only 1 or 2 of the existing translations. Notably, for most instruments, no information on conditions of use could be found online or in published studies. Instruments that did not require prior permission or registration were the 3 Headache-Attributed Lost Time (HALT) Indices, and the 3 versions of the WPAI. Additionally, items from the HLQ, Health and Labour Questionnaire-Short Form (SF-HLQ), PRODISQ, and quantity and quality method, were used to develop the more recently designed and validated iPCQ, which may therefore be seen as replacing and improving the previous instruments. The iPCQ was largely developed by the same research group involved in developing the instruments it replaces, and in doing so experiences with and evidence on the validity of the previous instruments was used.


Suitability for Use in Economic Evaluations

[Table 4](#) presents the assessment of the suitability of the included instruments for use in economic evaluations from a societal perspective in terms of identification, measurement, and valuation.

Identification of relevant cost components

From the 42 selected instruments, 32 (76.2%) contained questions on absenteeism, also 32 (76.2%) on presenteeism, and 14 (33.3%) on unpaid work. Eighteen instruments (42.9%) included 1 component (absenteeism, presenteeism, or unpaid work), 12 (28.6%) incorporated 2 components, and 12 (28.6%) contained all 3.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagrams of literature searches of economic evaluations and validation studies.



Operationalizing measurement

Thirty-four instruments provided data that allows for quantification of at least 1 component of productivity loss. Quantities of all 3 components were measured by the HALT-30 Index, SF-HLQ, HLQ, iPCQ, Migraine Disability Assessment (MIDAS), Valuation of

Lost Productivity Questionnaire, WPAI-GH, WPAI-Specific Health Problem, and WPAI-CIQ-SHP.

Monetary valuation

Four instruments could be used for the monetary valuation of productivity loss using the HCM by also providing information on

Table 2. Summary of study characteristics.

| Item | Category | N = 108 | %* |
|---------------------------|-----------------|--------------------|----|
| Country | The Netherlands | 28 | 26 |
| | United States | 23 | 21 |
| | United Kingdom | 10 | 9 |
| | Canada | 8 | 7 |
| | Spain | 8 | 7 |
| | Australia | 7 | 6 |
| | Germany | 7 | 6 |
| | Other | 40 | 37 |
| | Type of study | Cost-effectiveness | 49 |
| Cost-of-illness | | 47 | 44 |
| Cost-utility | | 42 | 39 |
| Validation | | 9 | 8 |
| Cost-benefit | | 1 | 1 |
| Productivity loss of whom | Patients | 98 | 91 |
| | Caregivers | 11 | 10 |
| | Parents | 1 | 1 |

*Total percentages may exceed 100 as certain studies were included in more than 1 category.

Table 3. Frequency of identified measurement instruments of productivity loss.

| Measurement instrument (abbreviation, version) | Frequency in economic evaluations | Frequency in validation studies | Total frequency |
|--|-----------------------------------|---------------------------------|-----------------|
| Work Productivity and Activity Impairment Questionnaire-General health (WPAI-GH, version 2.0) | 24 | 1 | 25 |
| Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP version 2.0) | 9 | 1 | 10 |
| iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P)* | 9 | 0 | 9 |
| Productivity and Disease Questionnaire (PRODISQ) | 7 | 0 | 7 |
| iMTA Productivity Cost Questionnaire (iPCQ) | 5 | 1 | 6 |
| Work Productivity and Activity Impairment (WPAI, no version specified)* | 5 | 0 | 5 |
| Health and Performance Questionnaire (HPQ, 7-day clinical trial version) | 4 | 1 | 5 |
| Client Service Receipt Inventory (CSRI)* | 4 | 0 | 4 |
| Health and Labour Questionnaire-Short Form (SF-HLQ) | 3 | 0 | 3 |
| Health and Labour Questionnaire (HLQ) | 3 | 0 | 3 |
| Migraine Disability Assessment (MIDAS) | 3 | 0 | 3 |
| Resource Utilization in Dementia (RUD) | 3 | 0 | 3 |
| Work Limitations Questionnaire (WLQ) | 2 | 0 | 2 |
| Quantity and Quality (Q-Q) | 1 | 1 | 2 |
| Stanford Presenteeism Scale (SPS-6) | 1 | 1 | 2 |
| Valuation of Lost Productivity Questionnaire (VOLP) | 1 | 1 | 2 |
| Health and Work Questionnaire (HWQ) | 0 | 2 | 2 |
| Client Sociodemographic and Service Receipt Inventory (CSSRI)* | 1 | 0 | 1 |
| Cost Interview | 1 | 0 | 1 |
| Family Cost Survey (FCS, version 1.0) | 1 | 0 | 1 |
| Health-Related Productivity Loss Instrument (HPLI) | 1 | 0 | 1 |
| MS Questionnaire | 1 | 0 | 1 |
| Patient Self-Assessment Questionnaire & Diary (SAQ) | 1 | 0 | 1 |
| Proforma for Cost of illness for Irritable Bowel Syndrome | 1 | 0 | 1 |
| Questionnaire by Agboola et al ⁴⁶ | 1 | 0 | 1 |
| Questionnaire by Tanvejsilp et al ⁴⁷ | 1 | 0 | 1 |
| Use of Services and Productivity Questionnaire (USPQ)* | 1 | 0 | 1 |
| Survey by Mumford et al ⁴⁸ | 1 | 0 | 1 |
| The cost diary by Goossens et al ⁴⁹ | 1 | 0 | 1 |
| Work and Health Interview (WHI) | 1 | 0 | 1 |
| Work Productivity and Activity Impairment plus Classroom Impairment (WPAI-CIQ-SHP, version 2) | 1 | 0 | 1 |
| Otago Cost and Consequences Questionnaire (OCC-Q) | 1 | 0 | 1 |
| Family Health Economic questionnaire* | 1 | 0 | 1 |
| Work absence question by Wynne-Jones et al ⁵⁰ | 1 | 0 | 0 |
| Work Productivity and Activity Impairment Questionnaire-General Healthcare Giving V2.0 (WPAI:GH-CG)* | 1 | 0 | 0 |
| Endicott Work Productivity Scale (EWPS) | 0 | 1 | 1 |
| Headache-Attributed Lost Time Indices 30 (HALT-30 Index) | 0 | 1 | 1 |
| Headache-Attributed Lost Time Indices 7/30 (HALT-7/30 Index) | 0 | 1 | 1 |
| Headache-Attributed Lost Time Indices 90 (HALT-90 Index) | 0 | 1 | 1 |
| Health Productivity Scale (HPS) | 0 | 1 | 1 |
| Job-Stress-Related Presenteeism Scale (JSRPS) | 0 | 1 | 1 |
| Lam Employment Absence and Productivity Scale (LEAPS) | 0 | 1 | 1 |
| Nurses Work Functioning Questionnaire (NWFQ) | 0 | 1 | 1 |

continued on next page

Table 3. Continued

| Measurement instrument (abbreviation, version) | Frequency in economic evaluations | Frequency in validation studies | Total frequency |
|--|-----------------------------------|---------------------------------|-----------------|
| Presenteeism Questions by Aronsson et al ⁵¹ | 0 | 1 | 1 |
| Question by Vänni et al ⁴⁰ | 0 | 1 | 1 |
| Resource Use Questionnaire-Preschool (RUQ-P) | 0 | 1 | 1 |
| Single item presenteeism question (SIPQ) | 0 | 1 | 1 |
| Work Hoarse (VRS-8) | 0 | 1 | 1 |
| Work Productivity Short Inventory (WPSI) | 0 | 1 | 1 |
| Total | 102 | 23 | 125 |

*Excluded from further analysis owing to identical productivity-loss questions, lack of information, or no original instrument.

long-term disability: the SF-HLQ, HLQ, iPCQ, and the Cost Interview. The SF-HLQ, HLQ, iPCQ, and PRODISQ enabled the use of the FCM by providing additional information on periods of absence from work.

Considering the previous criteria of suitability for use in economic evaluations simultaneously, the SF-HLQ, HLQ, and iPCQ, 3 generic instruments, provided quantified measures of the relevant components of productivity loss and enable monetary valuation with the FCM and HCM. Nevertheless, as described in the section on general characteristics, among others, the SF-HLQ and HLQ were replaced by the more recently developed iPCQ.

Discussion

This study identified 42 unique measurement instruments of productivity loss. Previous studies have found 16 of these. For instance, the WPAI-GH and the HLQ were also found in previous systematic reviews.^{13,14,16,18,20,21} In contrast, 26 of the included instruments in the current review were not identified in any of these previous reviews, for example the iPCQ, the HALT Indices, and the RUD.

Although many instruments were identified, our study found that most were not fully suitable for use in health economic evaluations from a societal perspective. This study aligns with previous studies finding that not all instruments include both absenteeism and presenteeism.^{13,14,16,18,21} Our study adds to this finding by focusing on productivity costs from both paid and unpaid work and discovering that few instruments included unpaid work loss. Nevertheless, a small number of instruments did enable the quantification of productivity loss for all 3 components. Although some instruments deliberately focus on the measurement of only 1 or 2 components, the current study can inform researchers on the relevant components of productivity loss that might not be included when relying on these instruments. Furthermore, as with the earlier review by Tang,¹⁶ the current study found that few instruments were compatible with the FCM. Supplementary to this observation, most instruments also did not provide information on long-term disability of respondents, therefore potentially causing a major underestimation of lifetime-productivity costs when applying the HCM. Importantly, some recent studies did not use the most recent instrument to measure productivity costs, but applied instruments that were replaced by newer instruments from the same developers. Thus, this review provides further evidence on the limited suitability of instruments to measure and value productivity loss for economic evaluations.

Therefore, future research should focus on using or developing instruments that are valid and suitable for this use.

A noticeable difference between the identified instruments is the length of the recall periods, which vary from 1 day to 2 years. Previous studies have highlighted that recall of events is subject to error and bias.^{88,89} Although longer recall periods generally result in less accurate estimates,⁹⁰⁻⁹² these might be necessary for capturing the impact on productivity loss due to infrequently occurring events or problems.⁷¹ Few studies have investigated recall periods of productivity loss to improve accuracy of memory recall and thus limit recall bias. For instance, Severens et al⁹³ advised using a recall period of no more than 2 months, or rather 4 weeks, for precision in self-reported absence from work. In contrast, Goetzel et al⁷¹ did not find different recall periods of absenteeism and presenteeism to have significantly different reliability. Hence, the literature about valid recall periods for questions absenteeism and presenteeism is inconclusive. Moreover, to our knowledge, no empirical evidence exists on the accuracy of recall periods for measuring unpaid production loss. As Stull et al⁹¹ suggested in their article on optimal recall periods for patient-reported outcomes, no single standard recall period is appropriate for measuring all outcomes. Phenomena that are more constant over time have a higher chance of being recalled accurately.⁹¹ In addition, salient events might allow for a longer recall period.⁹⁴ Therefore, differentiation between the recall periods of different components of productivity loss and medical costs might be necessary. Nevertheless, to our knowledge, no studies have investigated the effect of differing recall periods within 1 instrument on response accuracy. Additionally, recall period choices might depend on other factors as well, such as participant burden, costs, and measurement intervals,¹⁷ which should be considered for individual studies. Factors influencing researchers' motivations for specific recall periods were not included in this study. This study provides insight into the different recall periods used and highlights the need to investigate (factors influencing) optimal recall periods of measurement instruments of productivity loss. The recall periods identified in this review may be used as a starting point in a comparative study on the accuracy of outcomes.

Most identified instruments were designed for data collection from the patients themselves. Nevertheless, this might not be feasible in-patient groups with severe mental or physical illness or with cognitive disabilities. Thus, in the absence of previous studies, patient-proxy agreement in the measurement of productivity loss should be studied to provide insight into the accuracy of self-report of for instance parents or caregivers.

Table 4. General characteristics and suitability of measurement instruments of productivity loss for use in economic evaluations.

| Instrument name and abbreviation | General characteristics | | | | |
|---|-------------------------|------------------------|-------------------------|-------------------------------------|-------------------------------|
| | Focus of application | Mode of administration | Number of items (total) | Number of items (productivity loss) | Available online |
| Headache-Attributed Lost Time Indices 30 (HALT-30 Index) | Disease-specific | Self-report by patient | 5 | 4 | Yes, in English ⁵² |
| Headache-Attributed Lost Time Indices 90 (HALT-90 Index) | Disease-specific | Self-report by patient | 5 | 4 | Yes, in English ⁵² |
| Health and Labour Questionnaire-Short Form (SF-HLQ) | Generic | Self-report by patient | 14 | 11 | Yes, in English ⁵⁴ |
| Health and Labour Questionnaire (HLQ) | Generic | Self-report by patient | 23 | 11 | Yes, in English ⁵⁴ |
| iMTA Productivity Cost Questionnaire (iPCQ) | Generic | Self-report by patient | 18 | 14 | Not found |
| Migraine Disability Assessment (MIDAS) | Disease-specific | Self-report by patient | 5 | 4 | Yes ⁵⁸ |
| Resource Use Questionnaire-Preschool (RUQ-P) | Disease-specific | Interview of parent | 90 | 5 | Not found |
| Questionnaire by Agboola et al ⁴⁶ | Disease-specific | Self-report by patient | 37 | 13 | Yes ⁴⁶ |
| Valuation of Lost Productivity Questionnaire (VOLP) | Generic | Self-report by patient | 26 | 26 | Not found |
| Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP version 2.0) | Disease-specific | Self-report by patient | 6 | 6 | Yes ⁶¹ |
| Work Productivity and Activity Impairment plus Classroom Impairment (WPAI-CIQ-SHP, version 2) | Disease-specific | Self-report by patient | 10 | 6 | Yes ⁶¹ |
| Work Productivity and Activity Impairment Questionnaire-General health (WPAI-GH, version 2.0) | Generic | Self-report by patient | 6 | 6 | Yes ⁶¹ |
| Endicott Work Productivity Scale (EWPS) | Generic | Self-report by patient | 25 | Not found | Not found |
| Headache-Attributed Lost Time Indices 7/30 (HALT-7/30 Index) | Disease-specific | Self-report by patient | 5 | 4 | Yes, in English ⁵² |
| Health and Performance Questionnaire (HPQ, 7-day clinical trial version) | Generic | Self-report by patient | 21 | 12 | Yes ⁶⁴ |

NA indicates not applicable; NR, not reported.

[‡]instrument meets full requirement (ie, includes all components, provides quantified measures for all components, or is suitable for use of both valuation methods).

[†]instrument does not meet the requirement (ie, only includes 1 component, does not provide quantified measures for any of the components, or is not suitable for use of any of the valuation methods).

[‡]instrument meets partial requirement (ie, includes 2 of 3 components, provides quantified measures for 1 or 2 components, or is suitable for use of 1 valuation method).

Table 4. Continued

| Conditions of use | Languages | Recall period | Identification | Measurement | Valuation |
|---|--|------------------|---|--|---------------------------------------|
| | | | Components included | Allows for quantification | Suitable for common valuation methods |
| Can be freely used for clinical, research or other academic purposes ⁵³ | English, Dutch, French, German, Italian, Portuguese, and Spanish ⁵³ | 30 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| Can be freely used for clinical, research or other academic purposes ⁵³ | English, Dutch, French, German, Italian, Portuguese, and Spanish ⁵³ | 90 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism and presenteeism [‡] | No [†] |
| Not recommended for use since replacement with iPCQ, ⁵⁵ should not be used without prior consent ⁵⁶ | Dutch, English ⁵⁷ | 1 month | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | Yes, for HCM and FCM* |
| Not recommended for use since replacement with iPCQ, ⁵⁵ should not be used without prior consent ⁵⁶ | Dutch, English ⁵⁷ | 2 weeks | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | Yes, for HCM and FCM* |
| Available upon request, ⁵⁵ no further information found | English, Dutch, Czech, Danish, Finnish, French, German, Hungarian, Italian, Korean, Norwegian, Polish, Portuguese, Romanian, Spanish, and Turkish ⁵⁵ | 4 weeks | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | Yes, for HCM and FCM* |
| Not found | English ⁵⁸ | 3 months | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| Permission needed, ⁵⁹ no further information found | English, French (Canada) ⁵⁹ | 12 months | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism and unpaid work [‡] | No [†] |
| Not found | English ⁴⁶ | NR | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism [‡] | No [†] |
| Available upon request, ⁶⁰ no further information found | English (United Kingdom, Ireland), Dutch, French (Switzerland, France), German (Switzerland, Germany), Italian, Spanish, Arabic, Romanian, Polish, Hungarian, Norwegian, and Russian ⁶⁰ | 3 months, 7 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| No permission needed, no costs ⁶² | More than 40 languages, including English ⁶² | 7 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| No permission needed, no costs ⁶² | More than 20 languages, including English ⁶² | 7 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| No permission needed, no costs ⁶² | More than 20 languages, including English ⁶² | 7 days | Absenteeism, presenteeism, and unpaid work* | Yes, for absenteeism, presenteeism, and unpaid work* | No [†] |
| Not found | English, and Turkish ⁶³ | 1 week | Absenteeism and presenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Can be freely used for clinical, research or other academic purposes ⁵³ | English, Dutch, French, German, Italian, Portuguese, and Spanish ⁵³ | 7 and 30 days | Absenteeism and presenteeism [‡] | Yes, for absenteeism and presenteeism [‡] | No [†] |
| Not found | English, Spanish ⁶⁴ | 7 days | Absenteeism and presenteeism [‡] | Yes, for absenteeism and presenteeism [‡] | No [†] |

Table 4. General characteristics and suitability of measurement instruments of productivity loss for use in economic evaluations.

| Instrument name and abbreviation | General characteristics | | | | |
|---|-------------------------|--------------------------|-------------------------|-------------------------------------|---|
| | Focus of application | Mode of administration | Number of items (total) | Number of items (productivity loss) | Available online |
| Health-Related Productivity Loss Instrument (HPLI) | Generic | Self-report by patient | 6 | 5 | Not found |
| Lam Employment Absence and Productivity Scale (LEAPS) | Generic | Self-report by patient | 4 | 4 | Yes ⁶⁶ |
| Otago Costs and Consequences Questionnaire (OCC-Q) | Disease-specific | Self-report by patient | 38 | 6 | Not found |
| Productivity and Disease Questionnaire (PRODISQ) | Generic | Self-report by patient | 50 | 46 | Not found |
| Survey by Mumford et al ⁶⁹ | Disease-specific | Self-report by parent | 16 | 4 | Yes ⁴⁸ |
| The cost diary by Goossens et al ⁴⁹ | Generic | Self-report by patient | 11 | 1 | Yes ⁴⁹ |
| Work and Health Interview (WHI) | Generic | Interview of patient | 15 | Not found | Not found |
| Work Limitations Questionnaire (WLQ) | Generic | Self-report by patient | 5 | 5 | Not found |
| Work Productivity Short Inventory (WPSI) | Disease-specific | Self-report by patient | 22 | 19 | Yes ⁷¹ |
| Cost Interview | Disease-specific | Interview of patient | 85 | 8 | Not found |
| Family Cost Survey (FCS, version 1.0) | Disease-specific | Self-report by parent | 6 | 1 | Yes ⁷³ |
| Health and Work Questionnaire (HWQ) | Generic | Self-report by patient | 24 | 5 | Yes ⁵⁴ |
| Health Productivity Scale (HPS) | Generic | Self-report by patient | 29 | 29 | Yes ⁷⁴ |
| Job-Stress-Related Presenteeism Scale (JSRPS) | Generic | Self-report by patient | 6 | 6 | Yes ⁷⁵ |
| MS Questionnaire | Disease-specific | Interview of patient | 436 | 5 | Not found |
| Nurses Work Functioning Questionnaire (NWFQ) | Generic | Self-report by patient | 50 | 50 | Yes ⁷⁶ |
| Patient Self-Assessment Questionnaire & Diary (SAQ) | Disease-specific | Self-report by patient | 43 | 6 | Yes ⁷⁷ |
| Presenteeism Question by Aronsson et al ⁵¹ | Generic | Self-report by patient | 1 | 1 | Yes ⁴⁰ |
| Proforma for Cost of illness for Irritable Bowel Syndrome | Disease-specific | Self-report by patient | 37 | 10 | Yes ⁷⁸ |
| Quantity and Quality (Q-Q) | Generic | Self-report by patient | 2 | 2 | Yes ³⁰ |
| Question by Vänni et al ⁴⁰ | Generic | Self-report by patient | 1 | 1 | Yes ⁴⁰ |
| Questionnaire by Tanvejsilp et al ⁴⁷ | Disease-specific | Self-report by patient | 22 | 9 | Yes, in English ⁴⁷ |
| Resource Utilization in Dementia (RUD) | Disease-specific | Self-report by caregiver | 30 | 6 | Yes, in English ⁸⁰ |
| Single item presenteeism question (SIPQ) | Disease-specific | Self-report by patient | 1 | 1 | Yes ⁸¹ |
| Stanford Presenteeism Scale (SPS-6) | Generic | Self-report by patient | 6 | 6 | Yes, in English ⁸² and Dutch ⁸³ |
| Work absence question by Wynne-Jones et al ⁵⁰ | Disease-specific | Self-report by patient | 1 | 1 | Yes ⁵⁰ |
| Work Hoarse (VRS-8) | Disease-specific | Self-report by patient | 8 | 8 | Yes ⁸⁶ |

Although this study can contribute to the well-informed choice of which instrument to use in economic evaluations, this could still be challenging.⁸ The iPCQ appears to meet the criteria used in our current study and could therefore be recommended for use in economic evaluations. Nevertheless, specific economic evaluations might have specific needs for the measurement of productivity costs.

This review may then be helpful in purposely selecting another instrument. The search for consensus on and harmonization of methods of including, measuring and valuing productivity costs should continue, within and across countries and within international studies. Transparency on the use of a specific instrument and motivations for this decision might contribute to the choice process.

Table 4. Continued

| Conditions of use | Languages | Recall period | Identification | Measurement | Valuation |
|--|--|-------------------------------------|---|--|---------------------------------------|
| | | | Components included | Allows for quantification | Suitable for common valuation methods |
| Not found | English ⁶⁵ | 2 weeks | Absenteeism and presenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁶⁶ | 2 weeks | Absenteeism and presenteeism [‡] | Yes, for absenteeism and presenteeism [‡] | No [†] |
| Not found | English ⁶⁷ | 1 month | Absenteeism and presenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not recommended for use since replacement with iPCQ, ³⁵ prior registration (no fee) is required ⁶⁸ | Dutch ⁶⁸ | 3 months | Absenteeism and presenteeism [‡] | Yes, for absenteeism [‡] | Yes, for FCM [‡] |
| Not found | English ⁴⁸ | Variable period from admission date | Absenteeism and unpaid work [‡] | Yes, for absenteeism and unpaid work [‡] | No [†] |
| Not found | English ⁴⁹ | 1 week | Absenteeism and unpaid work [‡] | Yes, for absenteeism and unpaid work [‡] | No [†] |
| Not found | English ¹⁶ | 2 weeks | Absenteeism and presenteeism [‡] | Yes, for absenteeism and presenteeism [‡] | No [†] |
| Available upon request, ⁷⁰ no further information found | 28 languages, including English ⁷⁰ | 2 weeks | Absenteeism and presenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁷¹ | 1 year/3 months/2 weeks | Absenteeism and presenteeism [‡] | Yes, for absenteeism and presenteeism [‡] | No [†] |
| Not found | German ⁷² | 12 months | Absenteeism [‡] | Yes, for absenteeism [‡] | Yes, for HCM [‡] |
| Not found | English ⁷³ | NA | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁵⁴ | 1 week | Presenteeism [‡] | Yes, for presenteeism [‡] | No [†] |
| Not found | English ⁷⁴ | 30 days | Presenteeism [‡] | No [†] | No [†] |
| Not found | English ⁷⁵ | NR | Presenteeism [‡] | No [†] | No [†] |
| Not found | Spanish (Panama) ⁶⁹ | From symptom onset until today | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁷⁶ | 4 weeks | Presenteeism [‡] | No [†] | No [†] |
| Not found | English ⁷⁷ | NR | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁴⁰ | 12 months | Presenteeism [‡] | No [†] | No [†] |
| Not found | English ⁷⁸ | NR | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not recommended for use since replacement with iPCQ ⁷⁹ | English, Dutch ³⁰ | 1 day | Presenteeism [‡] | No [†] | No [†] |
| Not found | English ⁴⁰ | 2 years | Presenteeism [‡] | No [†] | No [†] |
| Not found | English, Thai ⁴⁷ | 1 day | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | 43 languages, including English ⁸⁰ | 30 days | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English, Persian ⁸¹ | 30 days | Presenteeism [‡] | Yes, for presenteeism [‡] | No [†] |
| Not found | English, ⁸² Dutch, ⁸³ Italian, ⁸⁴ Portuguese (Brazil) ⁸⁵ | 1 month | Presenteeism [‡] | No [†] | No [†] |
| Not found | English ⁵⁰ | 4 months | Absenteeism [‡] | Yes, for absenteeism [‡] | No [†] |
| Not found | English ⁸⁶ | 7 days | Presenteeism [‡] | No [†] | No [†] |

Limitations and Strengths of the Study

Potential limitations must be considered when interpreting the results of this study. First, although a very thorough search strategy was applied, the exclusion criteria might have resulted in

missing relevant studies. For instance, only English-language studies were included in this review. In contrast, a strength of this review is that instruments were not searched for in a direct way. By searching for economic evaluations that included either a societal perspective, indirect costs, or productivity costs, we were

able to include articles that did not mention productivity costs measurement instruments in their title or abstract.

Second, owing to feasibility reasons, economic evaluations and validation studies published before 2018 were excluded. Although a more elaborate review might have resulted in identifying additional measurement instruments, these instruments were, for some reason, then at least not applied in recent economic evaluations. Moreover, instruments that were only recently developed, or those that have had considerable research longevity, should have been found in the included validation studies.

Furthermore, in this review, measurement instruments were assessed using a predesigned data-extraction form to assess the suitability for use in economic evaluations. Although this elaborate form was composed with great care and with guidance from an international expert panel on productivity costs in economic evaluations, other aspects might be relevant for the instrument choice. Although validity and reliability were not assessed in the current study, which we think is an important issue to be addressed in future studies, we do provide information on whether the instruments could be used to measure and value the relevant components of productivity loss and thus were suitable for use in economic evaluations from a societal perspective. Furthermore, although this study was focused on absenteeism, presenteeism, and unpaid work, other components might also be relevant in the future. Some authors have suggested including compensation mechanisms and multiplier effects.^{4,16,95} Nevertheless, measuring these might be difficult as little is known about their effect on productivity costs. To accurately include multiplier effects and compensation mechanisms, also in the valuation stage, further research is needed into their actual effect on productivity costs, the relationship between these components, and how to accurately measure these effects in different contexts. Such research would also facilitate developing instruments that could measure these aspects in a valid manner. Moreover, it might not always be necessary to include absenteeism, presenteeism, and unpaid work and to enable monetary valuation using both the HCM and the FCM (eg, if national guidelines state to use only 1). In contrast, applying an instrument that meets these criteria might promote comparability within and across (international) studies because this instrument could be suitable for a variety of patient groups and countries.

Conclusions

Although many instruments for measuring productivity loss were identified, most were not suitable for use in health economic evaluations from a societal perspective. There is a need for national and international guidelines on the choice of measurement instrument to promote the comprehensive inclusion of productivity costs and enhance comparability and transferability within and across countries.

Supplemental Materials

Supplementary data associated with this article can be found in the online version at <https://doi.org/10.1016/j.jval.2021.05.002>.

Article and Author Information

Accepted for Publication: May 10, 2021

Published Online: xxxx

doi: <https://doi.org/10.1016/j.jval.2021.05.002>

Author Affiliations: Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands (Hubens, Brouwer, Uyl-de Groot, Hakkaart-van Roijen); IQVIA, Amsterdam, The Netherlands (Krol); Health Economics Bristol, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England, UK (Coast); Centre for Health Economics, University of York, York, England, UK (Drummond); Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands (Uyl-de Groot).

Correspondence: Kimberly Hubens, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam 300DR, The Netherlands. Email: k.hubens@gmail.com

Author Contributions: *Concept and design:* Hubens, Krol, Coast, Drummond, Brouwer, Uyl-de Groot, Hakkaart-van Roijen

Acquisition of data: Hubens

Analysis and interpretation of data: Hubens, Coast, Hakkaart-van Roijen

Drafting of the manuscript: Hubens, Krol, Drummond, Brouwer, Uyl-de Groot, Hakkaart-van Roijen

Critical revision of the paper for important intellectual content: Hubens, Krol, Coast, Drummond, Brouwer, Uyl-de Groot, Hakkaart-van Roijen

Statistical analysis: Hubens

Supervision: Brouwer, Uyl-de Groot

Conflict of Interest Disclosures: Ms Hubens and Drs Brouwer, Uyl-de Groot, and Hakkaart-van Roijen reported receiving grants from the European Union during the conduct of the study. No other disclosures were reported. Dr Drummond is an editor for Value in Health and had no role in the peer review process of this article.

Funding/Support: This study was part of the PECUNIA project and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 779292.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Acknowledgment: The authors would like to thank Wichor M. Bramer for optimizing the systematic literature search strategies and Donna Grobden for her help with the screening and data-extraction process. The authors would also like to thank Hannah Penton for offering a second opinion and in reaching consensus between the 2 screeners if needed.

REFERENCES

- Dang A, Likhari N, Alok U. Importance of economic evaluation in health care: an Indian perspective. *Value Heal Reg Issues*. 2016;9(6):78–83.
- Johannesson M, Jonsson B, Jonsson L, Kobelt G, Zethraeus N. Why should economic evaluations of medical innovations have a societal perspective? *Health Econ*. 2009;51:1–32.
- Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. *Eur J Heal Econ*. 2009;10(4):357–359.
- Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. *Pharmacoeconomics*. 2013;31(7):537–549.
- Walker S, Griffin S, Asaria M, Tsuchiya A, Sculpher M. Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision makers. *Appl Health Econ Health Policy*. 2019;17(5):577–590.
- Tan-Torres Edejer T, Baltussen R, Adam T, et al. *Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis*. Geneva, Switzerland: World Health Organization; 2003.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. 4th ed. Oxford, United Kingdom: Oxford University Press; 2015.
- Krol M. *Productivity Costs in Economic Evaluations*. Rotterdam, The Netherlands: Erasmus University Rotterdam; 2012.
- Krol M, Papenburg J, Tan SS, Brouwer W, Hakkaart L. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. *Eur J Heal Econ*. 2016;17(4):391–402.
- Luenigo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol*. 2013;14(12):1165–1174.
- De Putter CE, Selles RW, Polinder S, Panneman MJM, Hovius SER, Van Beek EF. Economic impact of hand and wrist injuries: health-care costs and productivity costs in a population-based study. *J Bone Joint Surg Am*. 2012;94(9):e56.

12. Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. *Pharmacoeconomics*. 2011;29(7):601–619.
13. Ospina MB, Dennett L, Waye A, Jacobs P, Thompson AH. A systematic review of measurement properties of instruments assessing presenteeism. *Am J Manag Care*. 2015;21(2):e171–e185.
14. Lofland JH, Pizzi L, Frick KD. A review of Health-Related Workplace Productivity Loss Instruments. *Pharmacoeconomics*. 2004;22(3):165–184.
15. Loeppke R, Hymel PA, Lofland JH, et al. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. *J Occup Environ Med*. 2003;45(4):349–359.
16. Tang K. Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. *Pharmacoeconomics*. 2015;33(1):31–48.
17. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. *Soc Sci Med*. 2011;72(2):185–192.
18. Noben CYG, Evers SMAA, Nijhuis FJ, De Rijk AE. Quality appraisal of generic self-reported instruments measuring health-related productivity changes: a systematic review. *BMC Public Health*. 2014;14(1):115.
19. Uegaki K, De Bruijne MC, Van Der Beek AJ, Van Mechelen W, Van Tulder MW. Economic evaluations of occupational health interventions from a company's perspective: a systematic review of methods to estimate the cost of health-related productivity loss. *J Occup Rehabil*. 2011;21(1):90–99.
20. Prasad M, Wahlqvist P, Shikhar R, Shih YCT. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. *Pharmacoeconomics*. 2004;22(4):225–244.
21. Matkic S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. *Am J Manag Care*. 2007;13(4):211–217.
22. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. *Ther Innov Regul Sci*. 2000;35(1):189–201.
23. Institute for Quality and Efficiency in Healthcare (IQWiG) [Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen], Institute for Quality and Efficiency in Health Care (IQWiG). General methods for the assessment of the relation between benefits and costs. 2009;V1.0:74.
24. Statens legemiddelverk (Norwegian Medicines Agency). Guidelines on how to conduct pharmacoeconomic analyses. 2012;974:1–27.
25. Hakkaart-Van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SS. *Kostenhandleiding: Methodologie van Kostenonderzoek en Referentieprijzen voor Economische Evaluaties in de Gezondheidszorg*. Rotterdam, The Netherlands: Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam; 2016.
26. Auquier P, Auray J, Berdeaux G, et al. French guidelines for the economic evaluation of health care technologies: methodological recommendations. https://tools.isspor.org/Peguidelines/source/France_Guidelines_HE_Evaluation.pdf. Accessed April 15, 2020.
27. Cleemput I, Neyt M, Van de Sande S, Thiry N. *Belgian Guidelines for Economic Evaluations and Budget Impact Analyses: Second Edition*. Brussels: Belgian Health Care Knowledge Centre; 2015.
28. Agency for Quality and Accreditation in Health Care. Department for Development Research and Health Technology Assessment. The Croatian Guideline for Health Technology Assessment Process and Reporting. 2011; (February):1–41.
29. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. *Health Econ*. 1997;6(3):253–259.
30. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity losses without absence: measurement validation and empirical evidence. *Health Policy (New York)*. 1999;48(1):13–27.
31. Fernández-Ballesteros R, Zamarrón MD, Díez-Nicolás J, López-Bravo MD, Molina MÁ, Schettini R. Productivity in old age. *Res Aging*. 2011;33(2):205–226.
32. Kigozi J, Jowett S, Lewis M, Barton P, Coast J. The estimation and inclusion of presenteeism costs in applied economic evaluation: a systematic review. *Value Heal*. 2017;20(3):496–506.
33. Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. *Pharmacoeconomics*. 2005;23(1):47–54.
34. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
35. *Endnote* [computer program]. London, United Kingdom: Clarivate Analytics; 2019.
36. Lofland JH, Frick KD. Publicly available US national surveys that capture lost productivity. *Expert Rev Pharmacoecon Outcomes Res*. 2002;2(5):485–494.
37. Reid M. *Economics of Household Production*. New York, NY: John Wiley & Sons, Inc; 1934.
38. Koopmanschap MA, Rutten FFH, Ineveld BM Van, Roijen L Van. The friction cost method for measuring indirect costs of disease. *J Health Econ*. 1995;14(2):171–189.
39. Brouwer WBF, Van Exel NJA, Koopmanschap MA, Rutten FFH. Productivity costs before and after absence from work: as important as common? *Health Policy (New York)*. 2002;61(2):173–187.
40. Vänni KJ, Neupane S, Siukola AE, et al. The Presenteeism Scale as a measure of productivity loss. *Occup Med*. 2018;68(8):512–518. <https://doi.org/10.1093/occmed/kqy124>.
41. Bouwmans C, De Jong K, Timman R, et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TIC-P). *BMC Health Serv Res*. 2013;13(1):217.
42. Breckons M, Shen J, Bunga J, Vale L, Durham J. DEEP study: indirect and out-of-pocket costs of persistent orofacial pain. *J Dent Res*. 2018;97(11):1200–1206.
43. Beecham J, Bonin EM, Görlich D, et al. Assessing the costs and cost-effectiveness of Icare internet-based interventions (protocol). *Internet Interv*. 2019;16:12–19.
44. Trang S, Zupancic JAF, Unger S, et al. Cost-effectiveness of supplemental donor milk versus formula for very low birth weight infants. *Pediatrics*. 2018;141(3):e20170737.
45. Reilly Associates. WPAI:GH V2.0. http://www.reillyassociates.net/WPAI_GH.html. Accessed April 15, 2020.
46. Agboola AA, Esan OT, Afolabi OT, Soyinka TA, Oluwaranti AO, Adetayo A. Economic burden of the therapeutic management of mental illnesses and its effect on household purchasing power. *PLoS One*. 2018;13(9):e0202396.
47. Tanvejsilp P, Loeb M, Dushoff J, Xie F. Out-of-pocket expenditures, indirect costs and health-related quality of life of patients with pulmonary tuberculosis in Thailand. *Pharmacoecon Open*. 2018;2(3):281–296.
48. Mumford V, Baysari MT, Kalinin D, et al. Measuring the financial and productivity burden of paediatric hospitalisation on the wider family network. *J Paediatr Child Health*. 2018;54(9):987–996.
49. Goossens MEJB, Rutten-van Mölken MP, Vlaeyen JWS, Van Der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. *J Clin Epidemiol*. 2000;53(7):688–695.
50. Wynne-Jones G, Artus M, Bishop A, et al. Effectiveness and costs of a vocational advice service to improve work outcomes in patients with musculoskeletal pain in primary care: a cluster randomised trial (SWAP trial ISRCTN 52269669). *Pain*. 2018;159(1):128–138.
51. Aronson G, Gustafson K, Dallner M. Sick but yet at work. An empirical study of sickness presenteeism. *J Epidemiol Community Health*. 2000;54:502–509.
52. Steiner TJ, Lipton RB, Al Jumah M. The Headache-Attributed Lost Time (HALT) Indices: measures of burden for clinical management and population-based research. *J Headache Pain*. 2018;19(1):12.
53. European Headache Federation. Lifting the burden. European principles of management of common headache disorders in primary care. https://www.i-t-b.org/assets/32/AD32D142-DA5C-077E-FA9391F46EE1D777_document/Principles_of_management.pdf. Accessed April 15, 2020.
54. EULAR OML. EULAR outcome measures library. <http://oml.eular.org/>. Accessed May 4, 2020.
55. iMTA. Questionnaires - iMTA. <https://www.imta.nl/questionnaires/>. Accessed May 4, 2020.
56. Hakkaart-van Roijen L, Essink-Bot M-L. Manual The Health and Labour Questionnaire. <http://hdl.handle.net/1765/1313>; 2000. Accessed April 15, 2020.
57. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FFH. Labor and health status in economic evaluation of health care: the health and labor questionnaire. *Int J Technol Assess Health Care*. 1996;12(3):405–415.
58. National Headache Foundation. Headache tests. <https://headaches.org/resources/headache-tests/>. Accessed June 24, 2020.
59. Ungar WJ, Tsiplova K, Millar N, Smith IM. Development of the Resource Use Questionnaire (RUQ-P) for families with preschool children with neurodevelopmental disorders: validation in children with autism spectrum disorder. *Clin Pract Pediatr Psychol*. 2018;6(2):164–178.
60. Centre for Health Evaluation & Outcome Sciences. The VOLP translations. <https://www.thevolp.com/use-the-volp/translations>. Accessed June 24, 2020.
61. Reilly Associates. WPAI general information. http://www.reillyassociates.net/WPAI_General.html. Accessed April 15, 2020.
62. Reilly Associates. WPAI translations. http://www.reillyassociates.net/WPAI_Translations.html. Accessed June 23, 2020.
63. Abma FI, van der Klink JJJ, Terwee CB, Amick BC, Bültmann U. Evaluation of the measurement properties of self-reported health-related work-functioning instruments among workers with common mental disorders. *Scand J Work Environ Heal*. 2012;38(1):5–18.
64. Harvard Medical School. World Health Organization health and work performance questionnaire. <https://www.hcp.med.harvard.edu/hpq/>. Accessed May 4, 2020.
65. Allen D, Hines EW, Pazdernik V, Konecny LT, Breitenbach E. Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study. *Hum Resour Heal*. 2018;16(1):59.
66. Lam RW, Michalak EE, Yatham LN. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. *BMC Psychiatry*. 2009;9:78.
67. Abbott JH, Wilson R, Pinto D, Chapple CM, Wright AA, MOA Trial Team. Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial. *Osteoarthritis Cartilage*. 2019;27(3):424–434.
68. Koopmanschap M, Meerding WJ, Evers S, et al. *Handleiding voor het Gebruik van PRODISQ versie 2.1 (PROductivity and Disease Questionnaire): Een*

- Modulaire Vragenlijst over de Relatie Tussen Ziekte En Productiviteitskosten. Toepasbaar Bij Economische Evaluaties van Gezondheidszorgprogramma's Voor Patiënten en Werknemers.* Rotterdam/Maastricht; 2004.
69. Gracia F, Larreategui M, Rodríguez G, et al. Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life. *PLoS One.* 2018;13(10):e0204681.
 70. Mapi research trust (MRT). Work Limitations Questionnaire (WLQ). <https://eprovide.mapi-trust.org/instruments/work-limitations-questionnaire2>. Accessed June 23, 2020.
 71. Goetzel RZ, Ozminkowski RJ, Long SR, Goetzel RZ, Long SR. Development and reliability analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *J Occup Environ Med.* 2003;45(7):743–762.
 72. Fassbinder E, Assmann N, Schaich A, et al. PRO*BPD: effectiveness of outpatient treatment programs for borderline personality disorder: a comparison of Schema therapy and dialectical behavior therapy: study protocol for a randomized trial. *BMC Psychiatry.* 2018;18(1):341.
 73. Hooshmand MA. Comparison of telemedicine to traditional face-to-face care for children with Special Health Care Needs: analysis of cost, caring, and family-centered care. <http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=109853918&site=ehost-live>. Accessed April 15, 2020.
 74. Gillespie GL, Gates DM, Succop P. Psychometrics of the healthcare productivity survey. *Adv Emerg Nurs J.* 2010;32(3):258–271.
 75. Gilbreath B, Karimi L. Supervisor behavior and employee presenteeism. *Int J Leadersh Stud.* 2012;7(1):114–131.
 76. Gärtner FR, Nieuwenhuijsen K, Van Dijk FJH, Sluiter JK. Impaired work functioning due to common mental disorders in nurses and allied health professionals: the Nurses Work Functioning Questionnaire. *Int Arch Occup Environ Health.* 2012;85(2):125–138.
 77. De Groot S, Enters-Weijnen CF, Geelhoed-Duijvestijn PH, Kanters TA. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. *BMJ Open.* 2018;8(3):e019864.
 78. Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai G. Effect of video-assisted patient education on compliance with therapy, quality of life, psychomorbidity, and cost of illness in irritable bowel syndrome. *Postgrad Med.* 2019;131(1):60–67.
 79. Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Roijen LH Van. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. *Value Heal.* 2015;18(6):753–758.
 80. Wimo A, Gustavsson A, Jonsson L, Winblad B, Hsu MA, Gannon B. Application of resource utilization in dementia (RUD) instrument in a global setting. *Alzheimers Dement.* 2013;9(4):6–17.
 81. Khanmohammadi M, Naghdi S, Ansari NN, Hadian MR, Kordi R, Hasson S. Single item presenteeism question: reliability and validity of Persian version in participants with low back pain. *Work.* 2018;61(3):339–346.
 82. Koopman C, Pelletier KR, Murray JF, et al. Stanford Presenteeism Scale: health status and employee productivity. *J Occup Environ Med.* 2002;44(1):14–20.
 83. Hutting N, Engels JA, Heerkens YF, Staal JB, Nijhuis-Van der Sanden MWG. Development and measurement properties of the Dutch version of the stanford presenteeism scale (SPS-6). *J Occup Rehabil.* 2014;24(2):268–277.
 84. Cicolini G, Della Pelle C, Cerratti F, Franza M, Flacco ME. Validation of the Italian version of the Stanford Presenteeism Scale in nurses. *J Nurs Manag.* 2016;24(5):598–604.
 85. Frauendorf R, de Medeiros Pinheiro M, Ciconelli RM. Translation into Brazilian Portuguese, cross-cultural adaptation and validation of the Stanford presenteeism scale-6 and work instability scale for ankylosing spondylitis. *Clin Rheumatol.* 2014;33(12):1751–1757.
 86. Zhu Q, Hu A, Giliberto JP, et al. Development of an instrument to assess work productivity in individuals with voice disorders: the work hoarse. *Ann Otol Rhinol Laryngol.* 2019;128(1):5–12.
 87. Thompson AH, Wayne A. Agreement among the productivity components of eight presenteeism tests in a sample of health care workers. *Value Heal.* 2018;21(6):650–657.
 88. Brown NR, Rips LJ, Shevell SK. The subjective dates of natural events in memory. *Cogn Psychol.* 1985;17(2):139–177.
 89. Kjellsson G, Clarke P, Gerdtham UG. Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions. *J Health Econ.* 2014;35(1):34–46.
 90. Clark DM, Teasdale JD. Diurnal variation in clinical depression and accessibility of memories of positive and negative experiences. *J Abnorm Psychol.* 1982;91(2):87–95.
 91. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. *Curr Med Res Opin.* 2009;25(4):929–942.
 92. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. *Med Care Res Rev.* 2006;63(2):217–235.
 93. Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in the Netherlands. *Soc Sci Med.* 2000;51(2):243–249.
 94. Eisenhower D, Mathiowetz NA, Morganstein D. Recall error: sources and bias reduction techniques. In: *Measurement Errors in Surveys.* New York, NY: John Wiley & Sons, Inc; 1991:127–144.
 95. Knies S, Boonen A, Candel MJJM, Evers SMAA, Severens JL. Compensation mechanisms for lost productivity: a comparison between four European countries. *Value Heal.* 2013;16(5):740–744.